About One Zyme

At One Zyme, we've seen how the sheer volume of scientific papers, clinical reports, and corporate disclosures can overwhelm even the most seasoned BD teams. Sorting through thousands of data points each week drains valuable time and risks letting breakthrough opportunities slip through the cracks. We solve this by embedding a fully dedicated AI team member into your organization—working around the clock to sift, score, and surface only the signals that matter most to you.

Our AI team member continuously aggregates discovery signals across preclinical pipelines, patent filings, funding announcements, and conference presentations. It then applies your custom criteria—therapeutic area, modality, trial stage, or strategic fit—to prioritize the highest-value opportunities. As soon as a new dataset or publication becomes available, your team gets an actionable digest, freeing you to focus on strategy, relationships, and deal execution.

One Zyme was born from the crossroads of venture capital and technology. Our founders have built high-scale platforms and grappled firsthand with data overload. They channeled that experience into an AI-driven solution designed to accelerate the pace of business development in science, ensuring your next big opportunity never hides in plain sight.

We're not just another analytics tool—we're an AI colleague that learns your interests, adapts to shifting priorities, and never sleeps. If you're ready to leave manual research behind and turn real-time intelligence into competitive advantage, you've come to the right place.